10 Most Promising Mid-Cap Healthcare Stocks According to Hedge Funds
In this article, we will take a look at some of the best mid-cap healthcare stocks that are being highly favored by hedge funds.
Dianthus Therapeutics Inc. (DNTH)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 2,611,733 | $219,176,633 | +63% | 2.32% |
| 2. | Avidity Partners Management David Witzke And Michael Gregory | 2,104,184 | $176,583,121 | 34.94% | |
| 3. | Octagon Capital Advisors Ting Jia | 1,946,667 | $163,364,295 | -20% | 18.08% |
| 4. | Citadel Investment Group Ken Griffin | 1,610,483 | $135,151,733 | +51% | 0.02% |
| 5. | Polar Capital Brian Ashford-Russell And Tim Woolley | 1,076,009 | $90,298,675 | +8% | 0.32% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.63 | 24,670 | $336,252.10 | 1,928,503 | 2023-09-29 | Filing | |
| $13.15 | 30,000 | $394,500.00 | 1,903,833 | 2023-09-26 | Filing | |
| $13.20 | 2,000 | $26,400.00 | 4,000 | 2023-09-22 | Filing | |
| $13.20 | 2,000 | $26,400.00 | 2,000 | 2023-09-21 | Filing | |
| $13.20 | 30,000 | $396,000.00 | 1,873,833 | 2023-09-19 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $91.37 | 4,159 | $380,007.83 | 4,000 | 2026-06-01 | Filing | |
| $90.72 | 16,943 | $1,537,068.96 | 8,159 | 2026-06-01 | Filing | |
| $89.72 | 5,428 | $487,000.16 | 25,102 | 2026-06-01 | Filing | |
| $85.47 | 599 | $51,196.53 | 0 | 2026-05-08 | Filing | |
| $89.84 | 8,224 | $738,844.16 | 0 | 2026-04-09 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 7,767,686 | $651,864,210 | 0.03% | |
| 2. | 3,175,703 | $266,504,995 | 0% | |
| 3. | 2,595,783 | $217,838,110 | 0.04% | |
| 4. | 2,537,191 | $212,921,069 | 15.38% | |
| 5. | 2,031,249 | $170,462,416 | 0% |
News See All
10 Best 52-Week High US Stocks to Buy
“Investors appear to be treating an end to the US-Israeli war with Iran as a foregone conclusion, as the S&P 500 closes above 7,000.” This is the deck on the New York Times’ report on the S&P 500...
Top 10 Boring Stocks That Make Money
Investors have been concentrating on businesses with solid fundamentals, steady cash flows, and long-lasting competitive advantages that can produce steady profit growth in a market influenced by fluctuating...
Guggenheim Reiterates Buy Rating for Dianthus Therapeutics (DNTH)
The adjustment follows updates to the firm’s model, which raised its estimates for claseprubart.
10 Most Shorted Biotech Stocks to Buy According to Hedge Funds
On February 5, J.P. Morgan shared its views on trends that are expected to define healthcare in 2026.
Clear Street Initiates Buy on Dianthus Therapeutics, Inc. (DNTH) With $100 Price Target
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is among the best fast money stocks to buy now. Clear Street assumed coverage on Dianthus Therapeutics, Inc.
11 Best Fast Money Stocks to Buy Now
In this fast-paced world, most people have become impatient. Everyone is drawn to whatever delivers quick results, whether it be fast fame or fast money.
Dianthus Therapeutics (DNTH) Hits New High as Drug Trial Sparks Optimism for Blockbuster Potential
Dianthus Therapeutics soared to a new record high on Monday, as investors cheered impressive results from its clinical trial of a potential treatment for generalized Myasthenia Gravis (gMG), a rare autoimmune...
Stifel Reaffirms Buy on Dianthus Therapeutics, Inc. (DNTH) with 186% Upside
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is among the best small company stocks to invest in. Stifel reaffirmed a Buy rating on Dianthus Therapeutics, Inc.
10 Best Small Company Stocks To Invest In
Most of the time, a company is overlooked because of its mere capitalization.